Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

Celldex (CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension, highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of ColdU and SD-the mast cell. The data were shared in a late breaking poster presentation at the 2026 American Academy of Allergy, Asthma & Immunology’s, AAAAI, Annual Meeting being held in Philadelphia, PA. The data were presented by Jonathan A. Bernstein, MD, trial investigator and Professor of Clinical Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine.